Аннотация
В условиях пандемии актуальным является ряд вопросов, касающихся применения генно-инженерной терапии: во-первых – это тактика ведения пациентов с хроническими заболеваниями, которые получают или являются кандидатами для использования в генно-инженерной терапии (ГИБТ), во-вторых – это данные о синдроме цитокинового шторма, наблюдаемом у пациентов с тяжелыми формами коронавирусной инфекции COVID-19, и целесообразности применения у них ГИБТ.
Литература
1. Yang X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // The Lancet Respiratory Medicine. – 2020. doi: 10.1016/S2213-2600(20)30079-5.
2. Augustin M. et al. Recommendations for systemic therapy in persons with psoriasis during the pandemic phase of SARS-COV-2 (corona virus). PsoNet; 2020. URL: https://www.psobesV.de/wp-content/uploads/2020/03/RundschreibenPsoBestPsoNetCoronafinalengl.1.1.pdf
3. Novel coronavirus 2019-nCoV. European Commission; 2019. URL: https://eP.europa.eu/health/coronavirus_en.
4. FDA. Novel coronavirus (2019-nCoV) URL: https://www.fda.gov/emergency-preparedness-and response/mcm-issues/novel-coronavirus-2019-ncov.
5. Wang V. et al. Comorbidities and multi-organ injuries in the treatment of COVID-19 //The LanceV. – 2020. – V. 395. – №. 10228. – P. e52. doi: 10.1016/S0140-6736(20)30558-4.
6. Yang J. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis //International Journal of Infectious Diseases. – 2020. doi: 10.1016/j.ijid.2020.03.017.
7. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? //The LanceV. Respiratory Medicine. – 2020. doi: 10.1016/S2213-2600(20)30116-8.
8. Hruza G.J. at al. Guidance on the use of biologic agents during COVID-19 outbreak. AAD; 2020. URL: https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf
9. Diao B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) // Frontiers in Immunology. – 2020. – V. 11. – P. 827. doi: 10.3389/fimmu.2020.00827.
10. Lau S. K. P. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment // Journal of General Virology. – 2013. – V. 94. – №. 12. – P. 2679-2690. doi: 10.1099/vir.0.055533-0.
11. Channappanavar R. et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice // Cell host & microbe. – 2016. – V. 19. – №. 2. – P. 181-193. doi: 10.1016/j.chom.2016.01.007
12. Yang X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // The Lancet Respiratory Medicine. – 2020. doi: 10.1016/S0140-6736( 20)30183- 5.
13. Yang Y. et al. Exuberant elevation of IP-10 // MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv. – 2020. – V. 2002. – P. 2020. doi: 10.1101/2020.03.02.20029975.
14. Chen L. et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia // Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases. – 2020. – V. 43. – P. E005-E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
15. Mehta P. et al. Correspondence COVID-19: consider cytokine storm syndromes and // LanceV. – 2020. – V. 6736. – №. 20. – P. 19-20. doi: 10.1016/S0140-6736(20)30628-0
16. Liu B. et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? // Journal of Autoimmunity. – 2020. – P. 102452. doi: 10.1016/j.jauV.2020.102452
17. Ye Q., Wang B., Mao J. Cytokine Storm in COVID-19 and Treatment // Journal of Infection. – 2020. doi: 10.1016/j.jinf.2020.03.037.
18. Xu X. et al. Effective treatment of severe COVID-19 patients with tocilizumab // Proceedings of the National Academy of Sciences. – 2020. doi: 10.1073/pnas.2005615117
19. Roumier M. et al. Interleukin-6 blockade for severe COVID-19 // Medrxiv. – 2020. doi: 10.1101/2020.04.20.20061861.
20. Bhimraj A. et al. Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19 // Clinical Infectious Diseases. – 2020. doi: 10.1093/cid/ciaa478.
21. Feldmann M. et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed // The LanceV. – 2020. – V. 395. – №. 10234. – P. 1407-1409. doi: 10.1016/S0140-6736(20)30858-8.
22. Qiu P. et al. Anti-tumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis // Critical care medicine. – 2013. – V. 41. – №. 10. doi: 10.1097/CCM.0b013e3182982add.
23. McDermott J. E. et al. The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus // BMC systems biology. – 2016. – V. 10. – №. 1. – P. 93. doi: 10.1186/s12918-016-0336-6.
24. Taylor P. P. et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis // Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. – 2000. – V. 43. – №. 1. – P. 38-47. doi: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L.
25. Xiong Y. et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients //Emerging Microbes & Infections. – 2020. – V. 9. – №. 1. – P. 761-770. doi: 10.1080/22221751.2020.1747363.
26. Shakoory B. et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial // Critical care medicine. – 2016. – V. 44. – №. 2. – P. 275. doi: 10.1097/CCM.0000000000001402.
27. Sallard E. et al. Type 1 interferons as a potential treatment against COVID-19 //Antiviral Research. – 2020. – P. 104791. doi: 10.1016/j.antiviral.2020.104791.
28. Lokugamage K. G. et al. SARS-CoV-2 sensitive to type I interferon pretreatment // BioRxiv. – 2020. doi: 10.1101/2020.03.07.982264.
29. Siddiqu H. K., Mehra M. R. COVID-19 Illness in Native and Immunosuppressed States // A Clinical-Therapeutic Staging Proposal. Journal of Heart and Lung Transplantation. – 2020. doi: 10.1016/j.healun.2020.03.012.
30. Shen K. L., Yang Y. H. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. – 2020. doi: 10.1007/s12519-020-00344-6.
31. Huang K. J. et al. An interferon‐γ‐related cytokine storm in SARS patients //Journal of medical virology. – 2005. – V. 75. – №. 2. – P. 185-194. doi: 10.1002/jmv.20255.
32. Wan S. et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) // MedRxiv. – 2020. doi: 10.1101/2020.02.10.20021832.
33. Song P. Y. et al. COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients // MedRxiv. – 2020.DOI: doi:.1101/2020.03.05.20031906.
34. Lagunas‐Rangel F. A., Chávez‐Valencia V. High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients // Journal of Medical Virology. – 2020. doi: 10.1002/jmv.25900.
35. Vallurupalli M., Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis // Blood. – 2019. – V. 134. – №. 21. – P. 1783-1786. doi: 10.1182/blood.2019002289
36. Jamilloux Y. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions // Autoimmunity Reviews. – 2020. – P. 102567. doi: 10.1016/j.autrev.2020.102567.
37. Arabi Y. M. et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study // Clinical infectious diseases. – 2020. – V. 70. – №. 9. – P. 1837-1844. doi: 10.1093/cid/ciz544.
38. Zumla A. et al. Coronaviruses—drug discovery and therapeutic options // Nature reviews Drug discovery. – 2016. – V. 15. – №. 5. – P. 327. doi: 10.1038/nrd.2015.37.
39. Qin Y. Y. et al. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial // Chinese Medical Journal. – 2020. doi: 10.1097/CM9.0000000000000791.
40. Gao J., Tian Z. Yang X. breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covId-19 associated pneumonia in clinical studies. Biosci Trends. – 2020. – V. 10. doi: 10.5582/bsV.2020.01047.
41. Jie Z. et al. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia // Zhonghua Jie He He Hu Xi Za Zhi. – 2020. – V. 43. – P. E019. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
42. Wang H. et al. Improvement of sepsis prognosis by ulinastatin: A systematic review and meta-analysis of randomized controlled trials // Frontiers in Pharmacology. – 2019. – V. 10. – P. 1370. doi: 10.3389/fphar.2019.01370.
43. Ju M. et al. Ulinastatin ameliorates LPS induced pulmonary inflammation and injury by blocking the MAPK/NF κB signaling pathways in rats // Molecular medicine reports. – 2019. – V. 20. – №. 4. – P. 3347-3354. doi: 10.3892/mmr.2019.10561.
44. Uccelli A., de Rosbo N. K. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways // Annals of the New York Academy of Sciences. – 2015. – V. 1351. – №. 1. – P. 114-126. doi: 10.1111/nyas.12815.
45. Ben-Mordechai V. et al. Targeting macrophage subsets for infarct repair // Journal of cardiovascular pharmacology and therapeutics. – 2015. – V. 20. – №. 1. – P. 36-51. doi: 10.1177/1074248414534916.